The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 354:644-645 February 9, 2006 Number 6
NextNext

Selective Adhesion-Molecule Therapy and Inflammatory Bowel Disease

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Podolsky, D. K.
-PubMed Citation
To the Editor: In his editorial, Podolsky (Nov. 3 issue)1 suggests that monitoring with the use of magnetic resonance imaging (MRI) may be helpful in the care of patients with Crohn's disease who are receiving natalizumab therapy and are at risk for progressive multifocal leukoencephalopathy (PML). This is not an ideal approach. The long-term safety and efficacy of natalizumab are relatively unknown, and there is a lack of clarity regarding the optimal duration of treatment beyond the trial period. In an experimental model of inflammatory colitis, long-term treatment with anti–{alpha} integrin antibodies resulted in disease exacerbation,2 indicating that the prolonged . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.